EQ
NASD Equillium, Inc.$1.41 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.41, $0.19 below the day’s high of $1.60
- YTD change
- -9.03%
- vs 20-day SMA
- -28.01%
- vs 200-day SMA
- -32.01%
Price ranges
Price & Performance
-0.60 (-29.85%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 94.8% away from all-time highs of $27.05
- EQ is down 9% since the beginning of the year
- EQ is down 4% over the past 12 months
- EQ is down 37% over the past 1 month
- 12% of all EQ investors are betting against EQ
EQ reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +6.0%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -18.02%
- vs 8-day SMA
- -16.66%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.